We are a life science-start-up that set out as a spin-off from Karolinska Institutet. We are committed to increase efficiency, safety and speed in the development of small molecules modulating the microbiome. We have developed an new technology that provides immediate information of the effect of new drug substances on the microbiome and facilitates the identification of phenotypic antimicrobial resistance.